BNET Industries
Market Cap:$3.0M
Last Fiscal Year Sales:$19.2M
- Public
- US
Dow Jones Description
Mfr, Developer & Marketer of Veterinary Diagnostics, Vaccines & Other Animal Health Related Products
President and CEO
Paul R. HaysNumber of Employees 100
Contact Information
12200 NW Ambassador Dr Ste 101
Kansas City, Missouri 64163
(858) 464-3500
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
News & Analysis
Filter by
healthcare and synbiotics corp. - All News and Analysis
Synbiotics Corporation Announces Approval of Witness Canine Heartworm Test
- 1998-07-28
SAN DIEGO--BUSINESS WIRE--July 28, 1998--Synbiotics Corporation (NASDAQ:SBIO) announced today that it has obtained U.S. Department of Agriculture approval to market WitnessrHW in the United States, the fastest and easiest to use product yet developed for the diagnosis of canine heartworm.WitnessrHW represents the latest Synbiotics innovation in easy-to-use diagnostic products for...
Synbiotics Corp. signs agreement to acquire International Canine Genetics Inc
- 1996-07-25
SAN DIEGO--BUSINESS WIRE--July 25, 1996--Synbiotics Corp. (NASDAQ:SBIO) and Malvern, Pa.-based International Canine Genetics Inc. (OTC Bulletin Board:ICGI;ICGIW), Thursday announced they have signed a definitive agreement under which International Canine Genetics ICG will be acquired by Synbiotics.The acquisition is subject to certain regulatory and stockholder approvals.Under the terms of the agreement,...
Synbiotics Corp. initiates employee benefits for veterinary care
- 1996-07-02
SAN DIEGO--BUSINESS WIRE--July 2, 1996--Synbiotics Corp. (NASDAQ:SBIO) Tuesday announced that the company is initiating an employee-benefit program to assist with covering the cost of veterinary care for employees' pets.Under this program, employees will be reimbursed for pet care provided by a licensed veterinarian.``Our business is developing, manufacturing and marketing animal...
Synbiotics posts modest profit; offering awaits SEC's approval
- 1987-04-27
Synbiotics posts modest profit; offering awaits SEC's approval Synbiotics Corp. finds itself in its strongest financial position ever while awaiting approval from the Securities and Exchange Commission for a public offering of 1.25 million shares of common stock. Revenues for the San Diego biomedical company for the year...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Paul R. Hays | President and CEO |
| Keith A. Butler | Cfo |
| B. Kent Luther | Vice President, Sales & Marketing |
| Chinta Lamichhane | Vice President, R & D |
| Clifford Frank | Vice President, Strategic Projects |
| Michael Harrod | Director of Technical Resources |
| Christophe Calleja | Marketing Manager |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald E Phillips | Chairman of the Board of Directors |
| Christopher P. Hendy | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | President and CEO | Current |
| Synbiotics Europe S.A.S. | President | Current |
| Synbiotics Corporation | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Cfo | Current |
| Synbiotics Corporation | Vice President | Current |
| Synbiotics Corporation | Board of Directors | Former |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Vice President, Sales & Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Vice President, R & D | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Vice President, Strategic Projects | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Director of Technical Resources | Current |
| Organization | Position | Status |
|---|---|---|
| Synbiotics Corporation | Marketing Manager | Current |
| Organization | Position | Status |
|---|---|---|
| Finds Ammonia | Current | |
| Synbiotics Corporation | Chairman of the Board of Directors | Current |
| Mississippi.Com | President | Former |
| Organization | Position | Status |
|---|---|---|
| Redwood Holdings, Inc. | Current | |
| Schonstedt Instrument Company | Board of Directors | Current |
| Synbiotics Corporation | Board of Directors | Current |
| Marine Midland Bank | Former | |
| Xavier University | B.S. Degree In Business Administration | Former |
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express